Left atrial thrombosis despite dabigatran therapy

Anil Pandit, Fayaz A. Hakim, Komandoor Srivathsan, John J. Lynch

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Dabigatran is a novel anticoagulation which has been approved as an alternative to warfarin therapy for non-valvular atrial fibrillation. Use of Dabigatran for approved indications as well as off label use has dramatically increased after Federal Drug Administration (FDA) approval. Our patient had left atrial thrombosis even after being on Dabigatran for more than one month which raises question about safety and efficacy of use of dabigatran around cardioversion and ablation..

Original languageEnglish (US)
Pages (from-to)31-32
Number of pages2
JournalJournal of Atrial Fibrillation
Volume6
Issue number2
StatePublished - Aug 1 2013

    Fingerprint

Keywords

  • Atrial fibrillation
  • Dabigatran
  • Left atrial thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Pandit, A., Hakim, F. A., Srivathsan, K., & Lynch, J. J. (2013). Left atrial thrombosis despite dabigatran therapy. Journal of Atrial Fibrillation, 6(2), 31-32.